Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
19. Dezember 2024 16:15 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
17. Juli 2024 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk...
CorVel Releases the New Integrated Claims Risk Score for Workers’ Compensation Claims, Leveraging Artificial Intelligence and Predictive Analytics
06. April 2022 07:22 ET
|
CorVel Corp.
The new functionality in CareMC Edge® assesses multiple factors to determine a claim risk score, helping claims professionals proactively address potential issues and positively impact overall...